Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | Mkt Perform | JMP Securities | |
| 1/23/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 3/16/2022 | $40.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $53.00 → $40.00 | Market Outperform | JMP Securities |
| 11/10/2021 | $44.00 → $53.00 | Outperform | Credit Suisse |
| 11/2/2021 | $46.00 → $53.00 | Market Outperform | JMP Securities |
| 9/21/2021 | $46.00 | Market Outperform | JMP Securities |
EFFECT - Inhibrx Biosciences, Inc. (0002007919) (Filer)
POS AM - Inhibrx Biosciences, Inc. (0002007919) (Filer)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
SAN DIEGO, May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.
SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered i
SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial state
JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform
JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform
SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00
SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste
Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying caus
SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma. We are building a seasoned, world-